{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:54:38Z","timestamp":1747166078124,"version":"3.40.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jscai.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Society for Cardiovascular Angiography &amp; Interventions"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jscai.2024.101859","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T20:57:02Z","timestamp":1711141022000},"page":"101859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1486-7452","authenticated-orcid":false,"given":"Dae Yong","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiun-Ruey","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-366X","authenticated-orcid":false,"given":"Kiara","family":"Goldwag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle D.","family":"Kelsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Elissa","family":"Altin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-8300","authenticated-orcid":false,"given":"Cesia","family":"Gallegos-Katt\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Nanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jscai.2024.101859_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes \u2013 global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J\u00a0Epidemiol Glob Health"},{"issue":"1","key":"10.1016\/j.jscai.2024.101859_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.jscai.2024.101859_bib3","first-page":"2464","article-title":"Impact of intensive glucose control in patients with diabetes mellitus undergoing percutaneous coronary intervention: 3-year clinical outcomes","volume":"9","author":"Park","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.jscai.2024.101859_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0735-1097(02)01971-X","article-title":"Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients","volume":"40","author":"Van Belle","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jscai.2024.101859_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003255","article-title":"Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients","volume":"9","author":"Koskinas","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.jscai.2024.101859_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jscai.2024.101859_bib7","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jscai.2024.101859_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/01.mca.0000085138.16622.9e","article-title":"Platelet abnormalities in diabetes mellitus","volume":"14","author":"Yazbek","year":"2003","journal-title":"Coron Artery Dis"},{"issue":"1","key":"10.1016\/j.jscai.2024.101859_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12963-018-0166-4","article-title":"Projection of the future diabetes burden in the United States through 2060","volume":"16","author":"Lin","year":"2018","journal-title":"Popul Health Metr"},{"issue":"3","key":"10.1016\/j.jscai.2024.101859_bib10","first-page":"e18","article-title":"2021 ACC\/AHA\/SCAI Guideline for\u00a0Coronary Artery Revascularization: a report of the American College of\u00a0Cardiology\/American Heart Association Joint Committee on Clinical Practice\u00a0Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"issue":"38","key":"10.1016\/j.jscai.2024.101859_bib11","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"year":"2023","series-title":"Comparison of different durations of dual antiplatelet therapy after percutaneous coronary intervention in diabetes mellitus: a systematic review and network meta-analysis","key":"10.1016\/j.jscai.2024.101859_bib12"},{"key":"10.1016\/j.jscai.2024.101859_bib13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jscai.2024.101859_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ahj.2022.05.019","article-title":"Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis","volume":"251","author":"Park","year":"2022","journal-title":"Am Heart J"},{"issue":"7650","key":"10.1016\/j.jscai.2024.101859_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jscai.2024.101859_bib16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jscai.2024.101859_bib17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jrsm.1460","article-title":"Zero-cell corrections in random-effects meta-analyses","volume":"11","author":"Weber","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jscai.2024.101859_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"10.1016\/j.jscai.2024.101859_bib19","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"issue":"18","key":"10.1016\/j.jscai.2024.101859_bib20","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jscai.2024.101859_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jscai.2024.101859_bib22","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.jscai.2024.101859_bib23","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.123.064264","article-title":"Comparison of 3- to 6-month versus 12-month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts: the HOST-IDEA randomized clinical trial","volume":"147","author":"Han","year":"2023","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jscai.2024.101859_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"14","key":"10.1016\/j.jscai.2024.101859_bib25","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"10.1016\/j.jscai.2024.101859_bib26","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jscai.2024.101859_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A\u00a0new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.jscai.2024.101859_bib28","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.jscai.2024.101859_bib29","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.jscai.2024.101859_bib30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jscai.2024.101859_bib31","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.jscai.2024.101859_bib32","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.jscai.2024.101859_bib33","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"10127","key":"10.1016\/j.jscai.2024.101859_bib34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"issue":"12_Supplement","key":"10.1016\/j.jscai.2024.101859_bib35","doi-asserted-by":"crossref","first-page":"A1859","DOI":"10.1016\/S0735-1097(14)61862-3","article-title":"Impact of short- versus long-term DAPT in patients with diabetes mellitus undergoing percutaneous intervention with Endeavor zotarolimus-eluting stents \u2013 A subanalysis of the large, prospective randomized, multicenter OPTIMIZE trial","volume":"63","author":"Feres","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jscai.2024.101859_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"10151","key":"10.1016\/j.jscai.2024.101859_bib54","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jscai.2024.101859_bib55","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: The IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"17","key":"10.1016\/j.jscai.2024.101859_bib37","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jscai.2024.101859_bib38","doi-asserted-by":"crossref","first-page":"i5483","DOI":"10.1136\/bmj.i5483","article-title":"Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials","volume":"355","author":"Gargiulo","year":"2016","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jscai.2024.101859_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242845","article-title":"Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"15","author":"Zhang","year":"2020","journal-title":"PLoS One"},{"issue":"4-5","key":"10.1016\/j.jscai.2024.101859_bib40","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.pcad.2017.12.003","article-title":"Duration of dual antiplatelet therapy following drug-eluting stent implantation in diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Sharma","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"issue":"9","key":"10.1016\/j.jscai.2024.101859_bib41","first-page":"781","article-title":"Optimal duration of dual antiplatelet therapy followed by monotherapy in diabetic patients after percutaneous coronary intervention with drug-eluting stent implantation: a Bayesian network meta-analysis","volume":"131","author":"An","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jscai.2024.101859_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/742719","article-title":"Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective","volume":"2011","author":"Kakouros","year":"2011","journal-title":"Int J Endocrinol"},{"issue":"2","key":"10.1016\/j.jscai.2024.101859_bib43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","article-title":"Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment","volume":"48","author":"Angiolillo","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"03","key":"10.1016\/j.jscai.2024.101859_bib44","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1160\/TH16-04-0322","article-title":"Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus","volume":"117","author":"Fejes","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jscai.2024.101859_bib45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jdiacomp.2014.01.006","article-title":"High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications","volume":"28","author":"Kim","year":"2014","journal-title":"J\u00a0Diabetes Complications"},{"issue":"7","key":"10.1016\/j.jscai.2024.101859_bib46","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jacc.2015.05.053","article-title":"Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence","volume":"66","author":"Montalescot","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jscai.2024.101859_bib47","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.jscai.2024.101859_bib48","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacc.2008.05.054","article-title":"Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel","volume":"52","author":"Ang","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jscai.2024.101859_bib49","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jscai.2024.101859_bib50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/0091270009337942","article-title":"Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38","volume":"49","author":"Wrishko","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.jscai.2024.101859_bib51","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation","volume":"7","author":"VAN Giezen","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"16","key":"10.1016\/j.jscai.2024.101859_bib52","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jscai.2024.101859_bib53","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"}],"container-title":["Journal of the Society for Cardiovascular Angiography &amp; Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772930324007087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772930324007087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T10:13:31Z","timestamp":1721643211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772930324007087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2772930324007087"],"URL":"https:\/\/doi.org\/10.1016\/j.jscai.2024.101859","relation":{},"ISSN":["2772-9303"],"issn-type":[{"type":"print","value":"2772-9303"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Society for Cardiovascular Angiography & Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jscai.2024.101859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of the Society for Cardiovascular Angiography and Interventions Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101859"}}